Serial testing of EBV DNA is considered to be a useful and noninvasive method for monitoring tumor response during neoadjuvant chemoradiotherapy.2 However, the value of EBV surveillance for patients with RM-NPC receiving anti–PD-1 immunotherapy is unclear. This evidence concerns the gene PDCD1 and neoplasm.